Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Xu, B; Saito, Y; Baumbach, A; Kelbæk, H; van Royen, N; Zheng, M; Morel, MA; Knaapen, P; Slagboom, T; Johnson, TW; Vlachojannis, G; Arkenbout, KE; Holmvang, L; Janssens, L; Ochala, A; Brugaletta, S; Naber, CK; Anderson, R; Rittger, H; Berti, S; Barbato, E; Toth, GG; Maillard, L; Valina, C; Buszman, P; Thiele, H; Schächinger, V; Lansky, A; Wijns, W; TARGET AC Investigators.
2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent.
JACC Cardiovasc Interv. 2019;
PubMed FullText FullText_MUG


Autor/innen der Med Uni Graz:
Toth-Gayor Gabor

Dimensions Citations:

Plum Analytics:
The aim of this study was to assess the 2-year clinical outcomes of the Firehawk stent, a novel abluminal groove-filled biodegradable-polymer sirolimus-eluting coronary stent, compared with XIENCE, a durable-polymer everolimus-eluting coronary stent. The long-term outcomes of the Firehawk stent have not been evaluated beyond 1 year in a randomized all-comers clinical trial. The TARGET All Comers study is a prospective, multicenter, all-comers, randomized, noninferiority trial conducted in Europe. A total of 1,653 patients were randomly assigned to undergo implantation of either the Firehawk or the XIENCE stent. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization. At 2-year follow-up, the incidence of target lesion failure was 8.7% in the Firehawk group versus 8.6% in the XIENCE group (p = 0.92). The event rates of individual components of the primary endpoint were comparable for the 2 groups. Landmark analyses between 1- and 2-year follow-up revealed no statistically significant difference of TLF for the Firehawk versus the XIENCE stent. Beyond 1 year, very late definite or probable stent thrombosis occurred in 3 patients (0.4%) in the Firehawk group and in 7 patients (0.9%) in the XIENCE group (p = 0.34). The 2-year follow-up of the TARGET All Comers study confirms comparable safety and efficacy profiles of the Firehawk and XIENCE stents. Copyright © 2019. Published by Elsevier Inc.

© Meduni Graz Impressum